Floatz logo

HAFNIUM OXIDE

Metastasis From Malignant Tumor of Bladder (Disorder)

NanobiotixOtherPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

22 Active assets in the Metastasis From Malignant Tumor of Bladder (Disorder) cohort.

Asset / SponsorPhaseRating
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Fred Hutchinson Cancer Center
Phase 2BB
Atezolizumab
National Cancer Institute (NCI)
Phase 2BB
Pembrolizumab
Fred Hutchinson Cancer Center
Phase 2BB
Carboplatin
Iambic Therapeutics, Inc
Phase 2BB
TRASTUZUMAB
Iambic Therapeutics, Inc
Phase 2BB

View all 45 →

Same molecule, other indications

HAFNIUM OXIDE is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
54 / 100
View asset →
Metastatic Malignant Neoplasm in the LungDormant
CCC
Indicative ·
48 / 100
View asset →
Advanced Malignant Solid NeoplasmDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →